◀ Back to VCAM1

SRC — VCAM1

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: VCAM1 → SRC (increases, SRC Translocation, VCAM1 Activity) Morel et al., J Biol Chem 2002*
  Evidence: In an alternate pathway, inhibition of IL-1 receptor-associated kinase-1 (IRAK) with AS ODN to IRAK reduced IL-18-induced expression of nuclear factor kappaB (NFkappaB). Finally, IL-18-induced cell surface VCAM-1 expression was inhibited by treatment with AS ODNs to c-Src, IRAK, PI3-kinase, and ERK1/2

Text-mined interactions from Literome

Seye et al., J Biol Chem 2004 (Arteriosclerosis) : Deletion or mutation of two Src homology-3 binding sites in the C-terminal tail of the P2Y(2)R or inhibition of Src kinase activity abolished the P2Y(2)R mediated transactivation of VEGFR-2 and subsequently inhibited UTP induced VCAM-1 expression
Amin et al., Blood 2006 : Antisense oligodeoxynucleotides ( ODNs ) and inhibitors of Src , PI3K, p38, and NFkappaB significantly reduced rhMIF induced MN VCAM-1 and ICAM-1 expression ( P < .05 )
Lin et al., Toxicol Appl Pharmacol 2008 : LPS stimulated Src, PYK2, EGFR, and Akt phosphorylation and VCAM-1 expression were attenuated by the inhibitors of Src ( PP1 ), EGFR ( AG1478 ), PI3-K ( LY294002 and wortmannin ), and Akt ( SH-5 ), respectively, or transfection with siRNAs of Src or Akt and shRNA of p110